Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA201A for Prevention of Corneal Endothelial Cell Loss in Cataract Surgery
NCT07694375Phase 2Recruiting
- Sponsor
- Caravel Oculus
- Start
- Jul 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 2 trial of ascorbic acid in corneal endothelial cell loss, sponsored by Caravel Oculus. Started Jul 2026; status: recruiting.
02
Drugs
ascorbic acid
03
Conditions
corneal endothelial cell loss
Beyond the preview
Go deeper on NCT07694375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07694375.